Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]
In development [GID-TA10690] Expected publication date: TBC
Search results
561 results
-
-
Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588
In development [GID-TA10507] Expected publication date: TBC
-
Type 2 diabetes in adults: management (update)
In development [GID-NG10160] Expected publication date: TBC
-
Diabetes update
In development [GID-NG10152] Expected publication date: TBC
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 09 March 2022
-
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]
In development [GID-TA10710] Expected publication date: TBC
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]
In development [GID-TA10708] Expected publication date: 22 December 2021
-
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
In development [GID-TA10527] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]
In development [GID-TA10477] Expected publication date: 22 September 2021
-
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442]
In development [GID-TA10672] Expected publication date: TBC
-
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
In development [GID-TA10780] Expected publication date: TBC
-
Thyroid cancer: assessment and management
In development [GID-NG10150] Expected publication date: 22 June 2022
-
Nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer [ID1676]
In development [GID-TA10743] Expected publication date: 17 November 2021
-
Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]
In development [GID-TA10520] Expected publication date: 15 September 2021
-
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]
In development [GID-TA10498] Expected publication date: 13 October 2021
-
Cenobamate for focal onset seizures in epilepsy [ID1553]
In development [GID-TA10661] Expected publication date: 13 October 2021
-
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]
In development [GID-TA10493] Expected publication date: TBC
-
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]
In development [GID-TA10650] Expected publication date: 25 August 2021
-
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]
In development [GID-TA10612] Expected publication date: 21 July 2021
-
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]
In development [GID-TA10624] Expected publication date: 23 June 2021
-
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]
In development [GID-TA10314] Expected publication date: TBC
-
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
In development [GID-TA10322] Expected publication date: TBC
-
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]
In development [GID-TA10370] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza [ID1537]
In development [GID-TA10559] Expected publication date: TBC
-
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]
In development [GID-TA10491] Expected publication date: TBC
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]
In development [GID-TA10538] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
-
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]
In development [GID-TA10470] Expected publication date: TBC
-
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]
In development [GID-TA10626] Expected publication date: 21 July 2021
-
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]
In development [GID-TA10482] Expected publication date: TBC
-
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
-
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
In development [GID-TA10244] Expected publication date: TBC
-
Atrial fibrillation: management
In development [GID-NG10100] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
In development [GID-TA10714] Expected publication date: 26 January 2022
-
Melanoma: assessment and management
In development [GID-NG10155] Expected publication date: 06 July 2022
-
AR101 for treating peanut allergy [ID1282]
In development [GID-TA10713] Expected publication date: 26 January 2022
-
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
In development [GID-TA10334] Expected publication date: TBC
-
Babies, children and young people's experience of healthcare
In development [GID-NG10119] Expected publication date: 25 August 2021
-
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
In development [GID-TA10483] Expected publication date: TBC
-
Asthma: diagnosis, monitoring and chronic asthma management
In development [GID-NG10186] Expected publication date: TBC
-
Mental wellbeing at work
In development [GID-NG10140] Expected publication date: 15 December 2021
-
Reducing sexually transmitted infections
In development [GID-NG10142] Expected publication date: 09 February 2022
-
Pernicious anaemia
In development [GID-NG10176] Expected publication date: 23 March 2023
-
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
-
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]
In development [GID-TA10619] Expected publication date: TBC
-
Galcanezumab for preventing cluster headache [ID1212]
In development [GID-TA10425] Expected publication date: 24 February 2021
-
Secukinumab for treating plaque psoriasis in children and young people [ID1669]
In development [GID-TA10554] Expected publication date: 20 October 2021
-
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in adults with elevated triglycerides [ID3831]
In development [GID-TA10736] Expected publication date: 05 January 2022